<p>Dianthus Therapeutics, Inc.（纳斯达克代码：DNTH - 获取免费报告）在 12 月份的空头头寸大幅增加。截至 12 月 31 日，空头头寸总计为 6,136,786 股，比 12 月 15 日的 4,164,492 股增加了 47.4%。根据 750,490 股的平均交易量，目前的覆盖天数比率为 8.2 天。大约 17.2% 的股票被做空。</p>
<p>获取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
<h2>Dianthus Therapeutics 价格表现</h2>
<p>Dianthus Therapeutics 股票在周五交易中上涨了 0.10 美元，达到 44.10 美元。该公司交易了 638,611 股，较其平均交易量 757,049 股有所减少。该公司的 50 日移动平均价格为 41.43 美元，200 日移动平均价格为 32.70 美元。Dianthus Therapeutics 的一年低点为 13.36 美元，一年高点为 46.59 美元。</p>
<p>Dianthus Therapeutics（纳斯达克代码：DNTH - 获取免费报告）最近于 11 月 5 日发布了季度财报。公司报告该季度每股收益为（0.97 美元），低于市场共识预期的（0.86 美元），差额为（0.11 美元）。该季度的收入为 40 万美元，而市场共识预期为 58 万美元。Dianthus Therapeutics 的股本回报率为负的 33.02%，净利润率为负的 4,106.04%。分析师平均预计 Dianthus Therapeutics 本年度每股收益为-2.61 美元。</p>
<h2>内部活动</h2>
<p>在其他 Dianthus Therapeutics 的新闻中，执行副总裁 Simrat Randhawa 于 11 月 14 日星期五出售了 109,031 股公司的股票，交易价格为每股 38.14 美元，总价值为 4,158,442.34 美元。交易完成后，该执行副总裁直接持有 4,000 股公司的股票，价值约 152,560 美元。此次交易使其持股减少了 96.46%。该出售在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Ryan Savitz 于 12 月 4 日星期四出售了 20,000 股股票，交易价格为每股 45.18 美元，总交易额为 903,600.00 美元。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 216,538 股公司股票，价值 8,283,175 美元。公司内部人士持有 8.15% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近增加或减少了在该公司的股份。Sio Capital Management LLC 在第二季度将其在 Dianthus Therapeutics 的持股增加了 101.8%。Sio Capital Management LLC 目前拥有 236,070 股公司股票，价值 4,398,000 美元，此前在该期间内增持了 119,073 股。XTX Topco Ltd 在第二季度购买了 Dianthus Therapeutics 的新头寸，价值约 503,000 美元。Ensign Peak Advisors Inc 在第二季度收购了 Dianthus Therapeutics 的新股份，价值约 2,504,000 美元。AlphaQuest LLC 在第二季度购买了 Dianthus Therapeutics 的新股份，价值约 94,000 美元。最后，Tower Research Capital LLC TRC 在第二季度将其在 Dianthus Therapeutics 的持股增加了 330.7%。Tower Research Capital LLC TRC 目前拥有 4,320 股公司股票，价值 80,000 美元，此前增持了 3,317 股。47.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>DNTH 最近成为多份研究报告的主题。Wedbush 在 12 月 22 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Dianthus Therapeutics 的目标价设定为 46.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Dianthus Therapeutics 的 “卖出（d-）” 评级。Truist Financial 在 1 月 8 日的研究报告中将 Dianthus Therapeutics 的目标价从 56.00 美元上调至 63.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 11 月 10 日的研究报告中将 Dianthus Therapeutics 的目标价从 40.00 美元上调至 47.00 美元，并给予该股票 “买入” 评级。八位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 64.43 美元。</p>
<p><strong>查看我们最新的 DNTH 股票报告</strong></p>
<h2>关于 Dianthus Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Dianthus Therapeutics, Inc.是一家临床阶段的生物技术公司，开发针对严重自身免疫和炎症性疾病的补充疗法。它正在开发 DNTH103，这是一种单克隆抗体，目前处于第二阶段临床试验中，旨在治疗广泛性重症肌无力、多发性运动神经病和慢性炎症性脱髓鞘性神经病。Dianthus Therapeutics, Inc.成立于 2019 年，总部位于纽约。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Dianthus Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>在 2026 年 5 月 20 日之前购买这只 2 美元的黄金股票</li>
<li>如果您在美国银行账户中存放现金……请立即阅读此信息</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Dianthus Therapeutics 吗？</h2>
<p>在考虑 Dianthus Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dianthus Therapeutics 并不在名单上。</p>
<p>虽然 Dianthus Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DNTH

<p>Dianthus Therapeutics, Inc.（纳斯达克代码：DNTH）在 12 月份的空头头寸显著增加，增长了 47.4%，达到 6,136,786 股。目前的空头头寸比率为 8.2 天，17.2% 的股份被卖空。该股票的交易价格为 44.10 美元，1 年价格区间为 13.36 美元至 46.59 美元。近期内部人士出售的股份总计 216,538 股，价值 828 万美元。机构投资者持有该股票的 47.53%，分析师设定的目标价格范围为 46.00 美元至 63.00 美元，评级从 “跑赢大盘” 到 “卖出” 不等</p>

<p>Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 6,136,786 shares, an increase of 47.4% from the December 15th total of 4,164,492 shares. Based on an average trading volume of 750,490 shares, the days-to-cover ratio is currently 8.2 days. Approximately 17.2% of the shares of the stock are short sold. Approximately 17.2% of the shares of the stock are short sold. Based on an average trading volume of 750,490 shares, the days-to-cover ratio is currently 8.2 days.</p>
<div class="lb-trans"><p>Dianthus Therapeutics, Inc.（纳斯达克代码：DNTH - 获取免费报告）在 12 月份的空头头寸大幅增加。截至 12 月 31 日，空头头寸总计为 6,136,786 股，比 12 月 15 日的 4,164,492 股增加了 47.4%。根据 750,490 股的平均交易量，目前的覆盖天数比率为 8.2 天。大约 17.2% 的股票被做空。</p>
</div><p>Get <strong>Dianthus Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
</div><h2>Dianthus Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Dianthus Therapeutics 价格表现</h2>
</div><p>Shares of Dianthus Therapeutics stock traded up $0.10 during trading on Friday, hitting $44.10. 638,611 shares of the company were exchanged, compared to its average volume of 757,049. The firm's fifty day moving average price is $41.43 and its 200 day moving average price is $32.70. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $46.59.</p>
<div class="lb-trans"><p>Dianthus Therapeutics 股票在周五交易中上涨了 0.10 美元，达到 44.10 美元。该公司交易了 638,611 股，较其平均交易量 757,049 股有所减少。该公司的 50 日移动平均价格为 41.43 美元，200 日移动平均价格为 32.70 美元。Dianthus Therapeutics 的一年低点为 13.36 美元，一年高点为 46.59 美元。</p>
</div><p>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. On average, equities analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.</p>
<div class="lb-trans"><p>Dianthus Therapeutics（纳斯达克代码：DNTH - 获取免费报告）最近于 11 月 5 日发布了季度财报。公司报告该季度每股收益为（0.97 美元），低于市场共识预期的（0.86 美元），差额为（0.11 美元）。该季度的收入为 40 万美元，而市场共识预期为 58 万美元。Dianthus Therapeutics 的股本回报率为负的 33.02%，净利润率为负的 4,106.04%。分析师平均预计 Dianthus Therapeutics 本年度每股收益为-2.61 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of the business's stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company's stock, valued at approximately $152,560. The trade was a 96.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 216,538 shares of company stock valued at $8,283,175 in the last 90 days. Corporate insiders own 8.15% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Dianthus Therapeutics 的新闻中，执行副总裁 Simrat Randhawa 于 11 月 14 日星期五出售了 109,031 股公司的股票，交易价格为每股 38.14 美元，总价值为 4,158,442.34 美元。交易完成后，该执行副总裁直接持有 4,000 股公司的股票，价值约 152,560 美元。此次交易使其持股减少了 96.46%。该出售在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，首席财务官 Ryan Savitz 于 12 月 4 日星期四出售了 20,000 股股票，交易价格为每股 45.18 美元，总交易额为 903,600.00 美元。该出售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士共出售了 216,538 股公司股票，价值 8,283,175 美元。公司内部人士持有 8.15% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sio Capital Management LLC raised its holdings in shares of Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company's stock worth $4,398,000 after acquiring an additional 119,073 shares during the period. XTX Topco Ltd bought a new position in Dianthus Therapeutics during the 2nd quarter worth about $503,000. Ensign Peak Advisors Inc acquired a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at about $2,504,000. AlphaQuest LLC bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $94,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了在该公司的股份。Sio Capital Management LLC 在第二季度将其在 Dianthus Therapeutics 的持股增加了 101.8%。Sio Capital Management LLC 目前拥有 236,070 股公司股票，价值 4,398,000 美元，此前在该期间内增持了 119,073 股。XTX Topco Ltd 在第二季度购买了 Dianthus Therapeutics 的新头寸，价值约 503,000 美元。Ensign Peak Advisors Inc 在第二季度收购了 Dianthus Therapeutics 的新股份，价值约 2,504,000 美元。AlphaQuest LLC 在第二季度购买了 Dianthus Therapeutics 的新股份，价值约 94,000 美元。最后，Tower Research Capital LLC TRC 在第二季度将其在 Dianthus Therapeutics 的持股增加了 330.7%。Tower Research Capital LLC TRC 目前拥有 4,320 股公司股票，价值 80,000 美元，此前增持了 3,317 股。47.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>DNTH has been the subject of a number of recent research reports. Wedbush restated an &#34;outperform&#34; rating and set a $46.00 target price on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, January 8th. Finally, HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, November 10th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $64.43.</p>
<div class="lb-trans"><p>DNTH 最近成为多份研究报告的主题。Wedbush 在 12 月 22 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Dianthus Therapeutics 的目标价设定为 46.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Dianthus Therapeutics 的 “卖出（d-）” 评级。Truist Financial 在 1 月 8 日的研究报告中将 Dianthus Therapeutics 的目标价从 56.00 美元上调至 63.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 11 月 10 日的研究报告中将 Dianthus Therapeutics 的目标价从 40.00 美元上调至 47.00 美元，并给予该股票 “买入” 评级。八位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 64.43 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on DNTH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 DNTH 股票报告</strong></p>
</div><h2>About Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dianthus Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.</p>
<div class="lb-trans"><p>Dianthus Therapeutics, Inc.是一家临床阶段的生物技术公司，开发针对严重自身免疫和炎症性疾病的补充疗法。它正在开发 DNTH103，这是一种单克隆抗体，目前处于第二阶段临床试验中，旨在治疗广泛性重症肌无力、多发性运动神经病和慢性炎症性脱髓鞘性神经病。Dianthus Therapeutics, Inc.成立于 2019 年，总部位于纽约。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Dianthus Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Dianthus Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>在 2026 年 5 月 20 日之前购买这只 2 美元的黄金股票</li>
<li>如果您在美国银行账户中存放现金……请立即阅读此信息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dianthus Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Dianthus Therapeutics 吗？</h2>
</div><p>Before you consider Dianthus Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dianthus Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Dianthus Therapeutics 并不在名单上。</p>
</div><p>While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dianthus Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dianthus Therapeutics, Inc.（纳斯达克股票代码：DNTH）在 12 月份的空头头寸增加了 47.4%